C4 Therapeutics, Inc. · NASDAQ:CCCC
Squadron Capital Management LLC reported a 6.90% stake in C4 Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
Squadron Capital Management LLC reported a 6.90% stake in C4 Therapeutics, Inc., 7,600,000 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 6.90%
- Shares
- 7,600,000
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Squadron Master Fund LP | 6.90% | 7,600,000 |
| Squadron Capital Management LLC | 6.90% | 7,600,000 |
| Matthew Sesterhenn | 6.90% | 7,600,000 |
| William Blank | 6.90% | 7,600,000 |
Source
Related
- C4 Therapeutics, Inc.
- Squadron Capital Management LLC
- C4 Therapeutics, Inc. shareholders
- Schedule 13G · Squadron Capital Management LLC · May 19, 2026
- Form 4 · Anderson Kenneth Carl · Oct 2, 2026
- Form 4 · Grogan Donna Roy · Oct 2, 2026
- Form 4 · Adams Kendra · Sep 21, 2026
- Schedule 13G/A · Lynx1 Capital Management LP · Aug 14, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Aug 14, 2026